NCT04247126 2023-10-27
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
Phase 1 Completed
Syros Pharmaceuticals
Eli Lilly and Company
Intergroupe Francophone de Cancerologie Thoracique
Translational Oncology Research International